Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition Target
January 09, 2017 at 07:51 AM EST
In the last part of our series on Calithera Biosciences we will be examining the company's second clinical asset and its acquisition chances sometime this year or early 2018.
